NCT00848562

Nicorandil Study to Reduce Cardiac Death After Percutaneous Coronary Intervention (PCI) in Hemodialysis Patients

Oral Nicorandil to Reduce Cardiac Death After Coronary Revascularization in Hemodialysis Patients: A Randomized Trial

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 129 (actual)
• Sponsor: Toujinkai Hospital · Academic / Other
• Sex: All
• Age: 30 Years
• Healthy volunteers: Not accepted

Summary

Survival after invasive coronary revascularization is worse in patients with chronic kidney disease than in those without it. The investigators aimed to examine whether oral administration of nicorandil, a hybrid of nitrate and adenosine triphosphate-sensitive potassium channel opener, could improve the survival of end-stage renal disease patients with coronary artery disease by inhibiting cardiac death after coronary revascularization.

Conditions

• Acute Myocardial Infarction
• Congestive Heart Failure

Interventions

Type	Name	Description
DRUG	Nicorandil	Oral administration of nicorandil (15 mg/day)

Timeline

• Start date: 2002-01-01
• Primary completion: 2006-12-01
• Completion: 2006-12-01
• First posted: 2009-02-20
• Last updated: 2009-02-20

Locations

1 site across 1 country: Japan